{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:11Z","timestamp":1790958251363,"version":"4.1.0"},"reference-count":4,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Background and Aims:<\/i><\/b> The aim of this study was to identify the utility of <sup>18<\/sup>F-fluorodeoxyglucose positron emission tomography\/computed tomography (<sup>18<\/sup>F-FDG-PET\/CT) as a predictor of early progressive disease (e-PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo\/Bev). <b><i>Methods:<\/i><\/b> Twenty consecutive patients with measurable intrahepatic target nodules who received Atezo\/Bev treatment were reviewed. The oncological aggressiveness of tumors estimated by <sup>18<\/sup>F-FDG-PET\/CT was analyzed using the rate of e-PD within 12 weeks and early progression-free survival (e-PFS) and overall survival (OS). Multivariate analysis was used to identify potential confounders for PD during Atezo\/Bev therapy. <b><i>Results:<\/i><\/b> Using the Response Evaluation Criteria in Solid Tumors version 1.1, a tumor-to-normal liver ratio (TLR) \u22652, indicating higher oncological aggressiveness in HCCs, was associated with lower objective response rates compared with TLR values &#x3c;2 (18% vs. 33%, respectively). Moreover, TLR values \u22652 were significantly associated with higher e-PD rates compared with TLR values &#x3c;2 (64% vs. 11%, respectively) and worse e-PFS (<i>p<\/i> = 0.021). In multivariate analysis, TLR \u22652 showed marginal significance as a predictor of e-PD (<i>p<\/i> = 0.053), and utility as a predictor for worse e-PFS (hazard ratio, 7.153; 95% confidence interval, 1.258\u201340.689; <i>p<\/i> = 0.027). In contrast, no significant differences in OS with\/without e-PD were observed during the treatment course. In this study, 8 patients experienced e-PD and almost 40% of patients experienced acceptable disease control following subsequent lenvatinib treatment. <b><i>Conclusion:<\/i><\/b> Pretreatment <sup>18<\/sup>F-FDG-PET\/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo\/Bev treatment of HCC. <\/jats:p>","DOI":"10.1159\/000523850","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T22:00:39Z","timestamp":1646172039000},"page":"320-330","source":"Crossref","is-referenced-by-count":15,"title":["Pretreatment Positron Emission Tomography with <sup>18<\/sup>F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma"],"prefix":"10.1159","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-0042","authenticated-orcid":false,"given":"Yusuke","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shindoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Muraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-2275","authenticated-orcid":false,"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-5552","authenticated-orcid":false,"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-3348","authenticated-orcid":false,"given":"Masaji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01200-x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000514312"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050352"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/523850","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/523850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:55:31Z","timestamp":1745423731000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000523850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":4,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,5,31]]}},"URL":"https:\/\/doi.org\/10.1159\/000523850","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.19276493","asserted-by":"subject"}]},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}